TY - JOUR
AU - Kissling, Esther
AU - Hooiveld, Mariëtte
AU - Martínez-Baz, Iván
AU - Mazagatos, Clara
AU - William, Naoma
AU - Vilcu, Ana-Maria
AU - Kooijman, Marjolein N.
AU - Ilić, Maja
AU - Domegan, Lisa
AU - Machado, Ausenda
AU - de Lusignan, Simon
AU - Lazar, Mihaela
AU - Meijer, Adam
AU - Brytting, Mia
AU - Casado, Itziar
AU - Larrauri, Amparo
AU - Murray, Josephine-Louise K.
AU - Behillil, Sylvie
AU - de Gier, Brechje
AU - Mlinarić, Ivan
AU - O'Donnell, Joan
AU - Rodrigues, Ana Paula
AU - Tsang, Ruby S.M.
AU - Timnea, Olivia
AU - de Lange, Marit
AU - Riess, Maximilian
AU - Castilla, Jesus
AU - Pozo, Francisco
AU - Hamilton, Mark
AU - Falchi, Alessandra
AU - Knol, Mirjam J.
AU - Filipović, Sanja Kurečić
AU - Dunford, Linda
AU - Guiomar, Raquel
AU - Cogdale, Jade
AU - Cherciu, Carmen
AU - Jansen, Tessa
AU - Enkirch, Theresa
AU - Basile, Luca
AU - Connell, Jeff
AU - Gomez, Veronica
AU - Martin, Virginia Sandonis
AU - Bacci, Sabrina
AU - Rose, Angela M.C.
AU - Celentano, Lucia Pastore
AU - Valenciano, Marta
AU - I-MOVE-COVID-19 and ECDC Primary Care Study Teams
PY - 2022
DA - May
TI - Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021
JO - Eurosurveillance
VL - 27
IS - 21
DO - https://doi.org/10.2807/1560-7917.ES.2022.27.21.2101104
AB - Coronavirus disease (COVID-19) has caused considerable morbidity and mortality with more than 66 million cases and 1.2 million deaths reported in the World Health Organization European Region as at 5 September 2021. The highly transmissible Delta variant (Phylogenetic Assignment of Named Global Outbreak (Pango) lineage designation B.1.617.2 and the AY sublineages) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) dominated over the Alpha variant (B.1.1.7) in Europe from July 2021 onwards and accounted for more than 99% of sequenced samples in weeks 35–36 in 2021. From mid-March 2021, four COVID-19 vaccines were authorised in the European Union by the European Medicines Agency: two mRNA vaccines (Comirnaty and Spikevax) and two adenoviral vector vaccines (Vaxzevria and COVID-19 Vaccine Janssen). Before the circulation of the Delta variant, randomised controlled trials indicated a high efficacy for these vaccines. Observational post-authorisation studies in Europe are therefore important to measure the effectiveness of the different COVID-19 vaccines against the currently circulating Delta variant.
PB - European Centre for Disease Prevention and Control
UR - https://publichealthscotland.scot/id/87496
KW - Coronavirus (COVID-19)
KW - Immunisation and screening
KW - Primary care
ER